Zuklopentyksol – Clopixol depot solution for in /mouse. enter oil 200 mg /ml 1 ml ampoules 10 pcs



Latin name Dlpf80

Release form

Solution for intramuscular injection (oil)


In an ampoule of 1 ml of solution. In a pack of cardboard 10 ampoules.

Pharmacological action

Clopixol Depot is an antipsychotic (antipsychotic) derivative of thioxanthene.

Clopixol has a pronounced antipsychotic and specific inhibitory effect. Clopixol may also have a transient, dose-dependent sedative effect, the rapid development of which at the beginning of therapy (before the onset of antipsychotic action) is an advantage in the treatment of acute and subacute psychoses.

Tolerance to the nonspecific sedative effect of the drug occurs rapidly.

Due to its specific inhibitory effect, the drug is especially indicated for agitation, anxiety, hostility or aggressiveness.

The therapeutic effect of clopixol depot is significantly more prolonged compared with clopixol. This allows you to confidently conduct continuous antipsychotic treatment with clopixol depot, which is especially important for patients who do not perform medical appointments.

Clopixol Depot prevents the development of frequent relapses associated with the arbitrary interruption of oral medication by patients.


– Acute and chronic schizophrenia and other psychotic disorders, especially with hallucinations, paranoid delusions and impaired thinking.

– States of agitation, increased anxiety, hostility, aggressiveness.


– Acute alcohol intoxication.

– Acute intoxication with barbiturates.

– Acute intoxication with opioid analgesics.

– Coma.

Use during pregnancy and lactation

Clopixol is not recommended for use during pregnancy and during lactation (breastfeeding).

Composition of

1 ml of oil solution contains:

active substance:

of zuclopentixol decanoate 200 mg

excipient of


Dosage and administration

The drug is prescribed as a deep intramuscular injection into the upper outer quadrant of the gluteal region.

Dose and interval between injections are determined individually depending on the condition of the patient.

Clopixol depot (200 mg / ml) with maintenance treatment is administered in doses of 200-400 mg (1-2 ml) every 2-4 weeks. In some cases, higher doses or a shorter interval between injections may be required.

– Transition from clopixol for oral administration to intramuscular injection of clopixol depot Daily dose (mg) of clopixol for oral administration x 8 = dose (mg) of clopixol depot for i / m administration once every 2 weeks. The intake of clopixol should be continued during the first week after the first injection, but in a reduced dose.

– Transition from intramuscular administration of clopixol-acuphase to intramuscular administration of clopixol depot 200-400 mg (1-2 ml) of clopixol depot (200 mg / ml) should be administered simultaneously with the final injection of clopixol-acuphase (100 mg). Repeated injections of clopixol depot are carried out every 2 weeks.

If necessary, the use of the drug in higher doses or a reduction in the interval between injections is permissible. Clopixol-acuphase and clopixol depot can be mixed in one syringe and administered as a single combined injection. Subsequent doses of clopixol depot and the intervals between injections should be set depending on the patient’s condition.

Side effects

Extrapyramidal disorders, tardive dyskinesia, malignant antipsychotic syndrome, drowsiness, dizziness, dry mouth, disturbance of accommodation are possible urinary retention, constipation, tachycardia, orthostatic hypotension, changes in liver tests.

Drug Interaction

When used concurrently, Clopixol may enhance the sedative effect of ethanol, barbiturates and other CNS depressant agents.

Clopixol should not be used concurrently with guanetidine and agents with a similar effect (since neuroleptics may block their antihypertensive effect).

When used with Clopixol, it can reduce the effectiveness of levodopa and other adrenergic agents.

The combined use of Clopixol with metoclopramide and piperazine increases the risk of extrapyramidal symptoms.

No pharmaceutical compatibility has been established.


Symptoms: drowsiness, coma, extrapyramidal disorders, seizures, hypotension, shock, hyper- or hypothermia.

Treatment: in case of ingestion it is necessary to wash the stomach as quickly as possible, the use of sorbent is recommended. Subsequently, symptomatic and supportive therapy is carried out. Steps should be taken to support the activities of the respiratory and cardiovascular systems. Adrenaline should not be used.

Storage conditions

Store in a dark place at a temperature not exceeding 25 ° C.


3 years.

Deystvuyuschee substances


dosage form

dosage form


H. Lundbeck A / O, Denmark